Navigation Links
New personalized treatment options for cancer
Date:12/19/2011

A new cancer research centre established at the University of Adelaide will focus on treatment options tailored to the individual, taking into account DNA and genetic variations between people.

The Centre for Personalised Cancer Medicine brings together a team of world-leading researchers with strengths in blood cancers and solid tumours, particularly breast, lung, sarcomas and melanoma.

Headed by Professor David Callen, the team will use tumour profiling and animal and cellular models to develop new drugs that target particular molecular changes in individual cancer patients.

"This centre reflects the trend towards a new, individualised approach to cancer medicine, taking into account genetic variations between people and their reaction to specific drugs," Professor Callen says.

"We will focus on improving the outcomes for cancer patients at all levels, from prevention through to treatment, survival, rehabilitation and palliative care, exploring novel and innovative approaches to cancer research.

"The big thrust at the moment is DNA sequencing. While it is still in the developmental stage, there are enormous resources being poured into this overseas and it looks like we will follow this lead in Australia."

The centre is already making headway in some areas, particularly in the treatment of sarcomas − rare malignant tumours which disproportionately affect young people and have a high mortality rate.

Dr Paul Neilsen, who oversees the Sarcoma Research Group, is collaborating with Royal Adelaide Hospital surgeon A/Prof Susan Neuhaus to trial new drugs on individual patient's tumours in a laboratory setting. "Currently these patients are treated with chemotherapy and radiotherapy but their outcomes are very poor and have not improved in the past decade," Dr Neilsen says.

"We have identified weak points in these tumours and are targeting them with new agents. The next step is to support pre-clinical trials in Australia."

Dr Neilsen lost his 18-year-old brother to Ewing's Sarcoma a malignant bone tumour which occurs most frequently in male teenagers and has a mortality rate of 40%, but increases to 90% for metastatic or recurrent disease.

Adelaide man John Marshall was a lot older 41 years of age when he was diagnosed with Ewing's Sarcoma in July 2010, undergoing surgery to remove the tumour, along with 12 months of chemotherapy.

"The diagnosis floored me. I was a fit, happy, healthy guy who had never smoked, ate a healthy diet and worked out regularly. How could this happen to me?"

While Mr Marshall has been given the all clear following his treatment, he is keen to support sarcoma research being undertaken at the Centre for Cancer Personalised Medicine and the Royal Adelaide Hospital. He is planning a sponsored cycle ride through the French Alps in September 2102.


'/>"/>
Contact: Professor David Callen
david.callen@adelaide.edu.au
61-882-223-145
University of Adelaide
Source:Eurekalert

Related medicine news :

1. New book by University of Louisville professor enables reader to develop personalized anti-depression plan
2. Northwestern to explore personalized medicine for scleroderma
3. Tumor-targeting compound points the way to new personalized cancer treatments
4. New and varied imaging techniques facilitate personalized medicine
5. Matching targeted therapies to tumors specific gene mutations key to personalized cancer treatment
6. Breast milk may provide a personalized screen of breast cancer risk
7. WSU researcher creates patented personalized therapy that causes cancer cells to kill themselves
8. IU Personalized Medicine Institute to develop targeted and individualized treatments
9. Tufts University calls for moderate approach to teaching personalized genomic testing
10. Personalized molecular therapy shows promising results for people with advanced lung cancer
11. Personalized vaccine for lymphoma patients extends disease-free survival by nearly 2 years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... February 20, 2017 , ... Chuck E. Cheese’s® and Center for Autism and ... at Chuck E. Cheese’s locations throughout New England, New York and New Jersey to ... experience the fun of visiting Chuck E. Cheese’s in a sensory-friendly environment. , ...
(Date:2/19/2017)... ... February 19, 2017 , ... Braun Industries will be participating as ... the event will take place February 23-25, 2017 at the Calvin L. Rampton Salt ... #909 with three new ambulances on display. , “JEMS is a ...
(Date:2/18/2017)... ... February 17, 2017 , ... ... Devicemakers , Sponsored by Axendia, **FDAnews Free Webinar**, March 1, 2017 — ... looking to reduce their regulatory burden? Pay dividends in enhanced and predictable ...
(Date:2/18/2017)... ... February 17, 2017 , ... Park Cities Pet Sitter ... Show on the Pet Life Radio network. The episode, which was posted this ... topics including: what factors led to Park Cities Pet Sitter’s being awarded the 2017 ...
(Date:2/17/2017)... ... February 17, 2017 , ... While EHR data has ... introduced an innovative workstation designed to reduce nursing fatigue while enhancing productivity. Based ... Workstation offers a lightweight, highly mobile, multi-functional alternative to the limitations of handheld ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... , Feb. 20, 2017   Orion Health ... its Amadeus precision medicine platform to the ... currently manages over 110 million patient records globally. ... developing cloud-based, big data solutions built on modern, scalable ... Healthcare and Life Sciences. "The AWS Cloud gives healthcare ...
(Date:2/20/2017)... , Feb. 20, 2017 Seal Shield ... health IT solution for mobile device management and disinfection, ... HIMSS Conference and Exhibition in Orlando, Fla. ... Mobile devices have become commonplace in today,s ... a new set of concerns, including the disinfection and ...
(Date:2/20/2017)... Feb. 20, 2017  There has been a paradigm ... (NCDs) across sub-Saharan Africa, which in turn is driving ... of more Western lifestyle diseases such as cardiovascular disease ... infectious and parasitic illness, will present the pharmaceutical industry ... opportunity of $40.8 billion in 2019. "An ...
Breaking Medicine Technology: